PURPOSE: Changes in GABA(A)-receptor density and affinity play an important role in many forms of epilepsy. A novel approach, using positron emission tomography (PET) and [C-11]flumazenil ([C-11]FMZ), was developed for simultaneous estimation of GABA(A)-receptor properties, characterized by B (max) and K (D). PROCEDURES: Following an injection of [C-11]FMZ (dose range: 1-2,000 mug) to 21 rats, concentration time curves of FMZ in brain (using PET) and blood (using HPLC-UV) were analyzed simultaneously using a population pharmacokinetic (PK) model, containing expressions to describe the time course of the plasma concentration (including distribution to the body), the brain distribution, and the specific binding within the brain. RESULTS: Application of this method in control rats resulted in estimates of B (max) and K (D) (14.5 +/- 3.7 ng/ml and 4.68 +/- 1.5 ng/ml, respectively). CONCLUSIONS: The proposed population PK model allowed for simultaneous estimation of B (max) and K (D) for a group of animals using single injection PET experiments per animal.
PURPOSE: Changes in GABA(A)-receptor density and affinity play an important role in many forms of epilepsy. A novel approach, using positron emission tomography (PET) and [C-11]flumazenil ([C-11]FMZ), was developed for simultaneous estimation of GABA(A)-receptor properties, characterized by B (max) and K (D). PROCEDURES: Following an injection of [C-11]FMZ (dose range: 1-2,000 mug) to 21 rats, concentration time curves of FMZ in brain (using PET) and blood (using HPLC-UV) were analyzed simultaneously using a population pharmacokinetic (PK) model, containing expressions to describe the time course of the plasma concentration (including distribution to the body), the brain distribution, and the specific binding within the brain. RESULTS: Application of this method in control rats resulted in estimates of B (max) and K (D) (14.5 +/- 3.7 ng/ml and 4.68 +/- 1.5 ng/ml, respectively). CONCLUSIONS: The proposed population PK model allowed for simultaneous estimation of B (max) and K (D) for a group of animals using single injection PET experiments per animal.
Authors: J Delforge; S Pappata; P Millet; Y Samson; B Bendriem; A Jobert; C Crouzel; A Syrota Journal: J Cereb Blood Flow Metab Date: 1995-03 Impact factor: 6.200
Authors: Anouk E Muller; Paul M Oostvogel; Joost DeJongh; Johan W Mouton; Eric A P Steegers; P Joep Dörr; Meindert Danhof; Rob A Voskuyl Journal: Antimicrob Agents Chemother Date: 2009-01-21 Impact factor: 5.191
Authors: Anouk E Muller; P Joep Dörr; Johan W Mouton; Joost De Jongh; Paul M Oostvogel; Eric A P Steegers; Rob A Voskuyl; Meindert Danhof Journal: Br J Clin Pharmacol Date: 2008-12 Impact factor: 4.335
Authors: Julia Müllauer; Claudia Kuntner; Martin Bauer; Jens P Bankstahl; Markus Müller; Rob A Voskuyl; Oliver Langer; Stina Syvänen Journal: EJNMMI Res Date: 2012-10-16 Impact factor: 3.138
Authors: Wilhelmus E A de Witte; Vivi Rottschäfer; Meindert Danhof; Piet H van der Graaf; Lambertus A Peletier; Elizabeth C M de Lange Journal: J Pharmacokinet Pharmacodyn Date: 2018-05-18 Impact factor: 2.745